Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 4

Efficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction.

Loma Linda University · NCT04860141

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–59 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 4
Target enrollment
98
US sites recruiting
1
Study start
June 16, 2021
Record last updated
February 4, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study is a double-blind, randomized, prospective, placebo-controlled single-center clinical research study in which 600 mg of gabapentin or placebo will be administered 2 hours preoperatively to 49 patients each undergoing wisdom teeth extraction. We will measure intraoperative opioid use, severity of pain, the number of analgesics taken, and side effect profiles (e.g. nausea/vomiting, dizziness) at the following intervals, 4 hour, 8 hour, 12 hour, 24, and 72 hour post-procedure.

Being studied: Gabapentin 600mg; Placebo

Conditions: Dental Pain and Sensation Disorder; Pain, Postoperative

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Subjects must be at or older than 18.
  • Screened body mass index (BMI) between 18-35 kg/m2.
  • American Society of Anesthesiologists Classification I and II.
  • Subjects must be willing and able to comply with protocol requirements.
  • Subjects must be able to understand the informed consent and must be able to sign a written informed consent form prior to the initiation of any study procedures.
  • A subject must have at least 1 partial or fully impacted third molar tooth removal.

Exclusion Criteria

  • hypersensitivity to gabapentinoids;
  • history of chronic opioid or gabapentin usage (regular use of opioids >3 months)
  • history of recreational drug usage
  • a history or clinical manifestations of significant metabolic, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urologic, musculoskeletal, psychiatric, or immunologic disorder, any acute, clinically significant illness or condition within 14 days prior to Day 1.
  • Patients with baseline pain.
  • Patients with any oral pathology will be excluded.
  • Pregnant or breastfeeding patients
  • An individual not legally competent to consent (e.g., incapacitated individuals, incompetents, minors)

Recruiting US locations

Study contacts (from the official record)

  • Je Dong Ryu, DMD MD · 909-558-4423 · jryu@llu.edu
  • Sung Han, DDS MD · 909-558-4423 · shan@llu.edu
All pain studies in California →